This study will study the potential utility of the Quantra QPlus System in patients inflicted with COVID-19 disease.
The Quantra System is a fully integrated and automated in vitro diagnostic device which uses SEER Sonorheometry, an ultrasound-based technology, to characterize the viscoelastic properties of a whole blood sample during coagulation. The QPlus Cartridge can measure hypocoagulable and hypercoagulable conditions resulting from the functional interaction of the enzymatic and cellular components of coagulation and therefore, can be invaluable for longitudinal monitoring of the coagulopathies reported in COVID-19 patients and the response to anticoagulants. This single-center, prospective, observational pilot study will characterize changes in the coagulation status of patients with COVID-19 infection during their hospital stay using the Quantra QPlus System.
Study Type
OBSERVATIONAL
Enrollment
15
Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
Texas Tech University Health Sciences Center El Paso
El Paso, Texas, United States
Quantra Clot Time results
Coagulation function assessed by the Quantra
Time frame: Within 24 hours of admission to the hospital
Quantra Clot Time results
Coagulation function assessed by the Quantra
Time frame: 48 to 72 hours after transfer to ICU
Quantra Clot Time results
Coagulation function assessed by the Quantra
Time frame: 1 to 24 hours prior to discharge from hospital
Quantra Clot Stiffness results
Coagulation function assessed by the Quantra
Time frame: Upon arrival at hospital
Quantra Clot Stiffness results
Coagulation function assessed by the Quantra
Time frame: 48 to 72 hours after transfer to ICU
Quantra Clot Stiffness results
Coagulation function assessed by the Quantra
Time frame: 1 to 24 hours prior to discharge from hospital
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.